Corbus Pharmaceuticals Holdings Inc CRBP 深 沪
已收盘 08-07 16:00:00 美东时间
10.17
+0.430
+4.41%
华盛通- 最 高10.23
- 今 开9.74
- 成交量 35.71万股
- 最 低 9.74
- 昨 收 9.74
- 总市值 1.88亿
- 52周最高 20.56
- 市盈率 静 --
- 换手率 1.93%
- 52周最低 7.12
- 委 比 -31.39%
- 总股本 1852.78万
- 历史最高 323.40
- 量 比 1.56
- 振 幅 5.03%
- 历史最低 3.00
- 每 手 1
- 风险率 2.37%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Oppenheimer Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $48
Oppenheimer analyst Jeff Jones maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $52 to $48.
08-07 21:58
Corbus Highlights Wider Loss and Strengthened Liquidity Position
Corbus Pharmaceuticals ( ($CRBP) ) has shared an announcement. Corbus Pharmaceu...
08-06 20:54
Corbus Pharmaceuticals Q2 EPS $(1.81) Misses $(1.26) Estimate
Corbus Pharmaceuticals (NASDAQ:CRBP) reported quarterly losses of $(1.81) per share which missed the analyst consensus estimate of $(1.26) by 43.65 percent. This is a 25.69 percent decrease over losses of $(1.44) per share from the same period last year.
08-06 20:32
Corbus Pharmaceuticals' Last Participant Completes Last Clinical Visit In Its CANYON-1 Phase 1b Clinical Study Of CRB-913 To Treat Obesity
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced the last patient has completed their last clinical visit ("Last Patient Last Visit") in the Company’s CANYON-1 Phase 1b clinical trial of CRB-913 for the t...
08-04 20:33
Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer
Corbus Pharmaceuticals Holdings announced FDA clearance to initiate the TEMPO-1 registrational study of CRB-701, a next-generation Nectin-4 targeted ADC, for second-line treatment of oropharyngeal squamous cell carcinoma (OPSCC). The randomized study (n=250) will compare CRB-701 to standard therapies, with objective response rate as the primary endpoint for potential accelerated approval. OPSCC incidence is rising due to HPV, affecting ~14,000 U....
07-28 12:00
Corbus Pharmaceuticals Appoints CMO Amid Key Trial Launches
Corbus Pharmaceuticals ( ($CRBP) ) has shared an update. On July 2, 2026, Corbu...
07-06 20:47
Corbus Pharmaceuticals appoints Leonardo Viana Nicacio as Chief Medical Officer
Corbus Pharmaceuticals Holdings (CRBP) announced the appointment of Leonardo Viana Nicacio as Chief Medical Officer. Nicacio brings over 20 years of pharmaceutical and oncology experience, notably ser...
07-06 20:14
Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer
Corbus Pharmaceuticals appoints Dr. Leonardo Viana Nicacio as Chief Medical Officer, bringing extensive experience in solid tumor drug development, including ADCs like TIVDAK® for metastatic cervical cancer. The company is set to initiate the TEMPO-1 registrational study for CRB-701 in 2L oropharyngeal squamous cell carcinoma (OPSCC) this summer. Dr. Nicacio emphasizes advancing CRB-701 and CRB-913 to address unmet needs in oncology and obesity, ...
07-06 12:00
美股大行评级 | 美银上调美光科技目标价从950美元升至1500美元，上调迈威尔科技目标价从240美元升至365美元
今日重点评级关注：摩根士丹利：维持杜邦"标配"评级，目标价从52美元升至156美元；蒙特利尔银行：维持Taysha Gene Therapies"跑赢大市"评级，目标价从10美元升至14美元
06-24 14:08
美股大行评级 | 花旗维持美光科技"买入"评级！目标价从840美元升至1200美元
今日重点评级关注：Chardan Capital：维持SAB Biotherapeutics"买入"评级，目标价从14美元升至16美元；Northland Capital Markets：维持Applied Digital"跑赢大市"评级，目标价从56美元升至82美元
06-18 19:08
